COVID‐19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?
Abstract Importance COVID‐19 is caused by SARS‐CoV‐2, a betacoronavirus that uses the angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) receptor to gain entry into cells. ACE2 receptor is widely expressed in multiple organs, including the retina, an extension of the central nervous system. The ACE2 receptor is involved in the diabetic and hypertensive retinopathy. Additionally, coronaviruses cause ocular infections in animals, including retinitis, and optic neuritis. Objective To assess whether there is any retinal disease associated with COVID‐19. Design We have evaluated 27 asymptomatic subjects, with retinal fundoscopic, optical coherence tomography (OCT) and OCT angiography fourteen days after hospital discharge due to COVID‐19 bilateral pneumonia. Results Cotton wool exudates were evident in six out of 27 patients evaluated, a 22%. Cotton wool exudates are a marker vascular disease severity in other medical context, that is diabetes and hypertension, and are associated with increased risk for acute vascular events. Whether antiaggregation therapy may play a role on fundoscopic‐selected patients with COVID‐19 requires prospective trials..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:289 |
|---|---|
| Enthalten in: |
Journal of Internal Medicine - 289(2021), 1, Seite 116-120 |
| Beteiligte Personen: |
Landecho, M. F. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 The Association for the Publication of the Journal of Internal Medicine |
|---|
| Umfang: |
5 |
|---|
| doi: |
10.1111/joim.13156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY009225838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY009225838 | ||
| 003 | DE-627 | ||
| 005 | 20230307184516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/joim.13156 |2 doi | |
| 028 | 5 | 2 | |a JOIM_JOIM13156.xml |
| 035 | |a (DE-627)WLY009225838 | ||
| 035 | |a (WILEY)JOIM13156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Landecho, M. F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID‐19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? |
| 264 | 1 | |c 2021 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 The Association for the Publication of the Journal of Internal Medicine | ||
| 520 | |a Abstract Importance COVID‐19 is caused by SARS‐CoV‐2, a betacoronavirus that uses the angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) receptor to gain entry into cells. ACE2 receptor is widely expressed in multiple organs, including the retina, an extension of the central nervous system. The ACE2 receptor is involved in the diabetic and hypertensive retinopathy. Additionally, coronaviruses cause ocular infections in animals, including retinitis, and optic neuritis. Objective To assess whether there is any retinal disease associated with COVID‐19. Design We have evaluated 27 asymptomatic subjects, with retinal fundoscopic, optical coherence tomography (OCT) and OCT angiography fourteen days after hospital discharge due to COVID‐19 bilateral pneumonia. Results Cotton wool exudates were evident in six out of 27 patients evaluated, a 22%. Cotton wool exudates are a marker vascular disease severity in other medical context, that is diabetes and hypertension, and are associated with increased risk for acute vascular events. Whether antiaggregation therapy may play a role on fundoscopic‐selected patients with COVID‐19 requires prospective trials. | ||
| 700 | 1 | |a Yuste, J. R. |4 aut | |
| 700 | 1 | |a Gándara, E. |4 aut | |
| 700 | 1 | |a Sunsundegui, P. |4 aut | |
| 700 | 1 | |a Quiroga, J. |4 aut | |
| 700 | 1 | |a Alcaide, A. B. |4 aut | |
| 700 | 1 | |a García‐Layana, A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Internal Medicine |g 289(2021), 1, Seite 116-120 |w (DE-627)WLY009222359 |x 13652796 |7 nnns |
| 773 | 1 | 8 | |g volume:289 |g year:2021 |g number:1 |g pages:116-120 |g extent:5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.61 |q ASE |
| 951 | |a AR | ||
| 952 | |d 289 |j 2021 |e 1 |h 116-120 |g 5 | ||